ARGX

709.8

+1.66%↑

SHL.DE

34.5

-2.02%↓

PHIA

22.53

-2.38%↓

FRE

36.35

-2.55%↓

SRT3

232.1

-1.23%↓

ARGX

709.8

+1.66%↑

SHL.DE

34.5

-2.02%↓

PHIA

22.53

-2.38%↓

FRE

36.35

-2.55%↓

SRT3

232.1

-1.23%↓

ARGX

709.8

+1.66%↑

SHL.DE

34.5

-2.02%↓

PHIA

22.53

-2.38%↓

FRE

36.35

-2.55%↓

SRT3

232.1

-1.23%↓

ARGX

709.8

+1.66%↑

SHL.DE

34.5

-2.02%↓

PHIA

22.53

-2.38%↓

FRE

36.35

-2.55%↓

SRT3

232.1

-1.23%↓

ARGX

709.8

+1.66%↑

SHL.DE

34.5

-2.02%↓

PHIA

22.53

-2.38%↓

FRE

36.35

-2.55%↓

SRT3

232.1

-1.23%↓

Home・Akcijų sąrašas・Sanofi SA

Search

Sanofi SA

Atidarymo kaina

SektoriusSveikatos priežiūra

76.05 -1.49

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

75.57

Max

77.32

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-394M 1.6B
Pardavimai	-12B 11B
P/E Sektoriaus vid.	19.273 50.102
Pelnas, tenkantis vienai akcijai	1.34
Pelno marža	14.354
Darbuotojai	74,846
EBITDA	1.5B 2.7B

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+24.76% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-07-30

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-7.5B 91B
Ankstesnė atidarymo kaina	77.54
Ankstesnė uždarymo kaina	76.05

Naujienos nuotaikos

By Acuity

62%

38%

282 / 344 reitingas Healthcare

Sanofi SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-29 09:03; UTC

Uždarbis

Spain's Santander Profit Climbs Amid Global Portfolio Reshuffle -- Update

2026-04-29 05:27; UTC

Uždarbis

Santander Books Jump in Profit on Top-Line Growth, Lower Costs

2026-04-23 06:12; UTC

Uždarbis

Sanofi Posts Higher Sales Amid Leadership Transition

2026-05-27 20:34; UTC

Įsigijimai, susijungimai, perėmimai

Webster Financial Stockholders Approve Sale to Banco Santander

2026-05-07 06:47; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Sanofi Needs Acquisitions to Overcome Pipeline Disappointments -- Market Talk

2026-05-01 06:14; UTC

Įsigijimai, susijungimai, perėmimai

Santander UK to Also Pay GBP213M Based on TSB's Tangible NAV

2026-05-01 06:13; UTC

Įsigijimai, susijungimai, perėmimai

Santander UK Also Financed Deal From Funding by Parent, Banco Santander

2026-05-01 06:12; UTC

Įsigijimai, susijungimai, perėmimai

Santander UK Financed Deal From Existing Cash Resources

2026-05-01 06:08; UTC

Įsigijimai, susijungimai, perėmimai

Santander UK Announced Key Terms of Deal July 2025

2026-05-01 06:03; UTC

Įsigijimai, susijungimai, perėmimai

Santander UK Buys TSB Banking for GBP2.65B

2026-05-01 06:02; UTC

Įsigijimai, susijungimai, perėmimai

Santander UK Buys TSB Banking Group

2026-04-29 12:01; UTC

Uždarbis

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

2026-04-29 06:27; UTC

Rinkos pokalbiai

Uždarbis

Santander's Above-Forecast Earnings Should Be Well-Received -- Market Talk

2026-04-29 04:55; UTC

Uždarbis

Analysts Saw Santander 1Q Loan Loss Provisions EUR3.12B

2026-04-29 04:55; UTC

Uždarbis

Santander 1Q Loan Loss Provisions EUR3.225B

2026-04-29 04:54; UTC

Uždarbis

Analysts Saw Santander 1Q Operating Expenses EUR6.57B

2026-04-29 04:54; UTC

Uždarbis

Santander 1Q Operating Expenses EUR6.48B

2026-04-29 04:52; UTC

Uždarbis

Santander Backs 2028 View

2026-04-29 04:52; UTC

Uždarbis

Santander Backs 2026 View

2026-04-29 04:52; UTC

Uždarbis

Santander 1Q Underlying RoTE 15.2%

2026-04-29 04:51; UTC

Uždarbis

Santander End-1Q CET1 Ratio 14.4%

2026-04-29 04:51; UTC

Uždarbis

Analysts Saw Santander 1Q Net Interest Income EUR10.86B

2026-04-29 04:51; UTC

Uždarbis

Santander 1Q Net Interest Income EUR11.02B

2026-04-29 04:50; UTC

Uždarbis

Analysts Saw Santander 1Q Underlying Net Pft EUR3.47B

2026-04-29 04:50; UTC

Uždarbis

Santander 1Q Underlying Pft EUR3.56B

2026-04-29 04:49; UTC

Uždarbis

Santander 1Q Net Pft EUR5.455B

2026-04-29 04:49; UTC

Uždarbis

Analysts Saw Santander 1Q Rev EUR15.00B

2026-04-29 04:49; UTC

Uždarbis

Santander 1Q Rev EUR15.14B

2026-04-27 09:32; UTC

Rinkos pokalbiai

Uždarbis

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

2026-04-27 09:19; UTC

Rinkos pokalbiai

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

Akcijų palyginimas

Kainos pokytis

Sanofi SA Prognozė

Kainos tikslas

By TipRanks

24.76% į viršų

12 mėnesių prognozė

Vidutinis 95.22 EUR 24.76%

Aukščiausias 107 EUR

Žemiausias 85 EUR

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sanofi SA kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

4

Pirkti

5

Laikyti

0

Parduoti

Remiantis 9 analitikų, pateikusių Sanofi SA akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

282 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Kitos sektoriaus akcijos

ARGX

Argenx SE

709.8

SHL.DE

Siemens Healthineers AG

34.5

PHIA

Koninklijke Philips NV

22.53

FRE

Fresenius SE & Co KGaA

36.35

SRT3

Sartorius AG

232.1

Live chat